Similarly to the TC-1/dCD80-1-induced tumors, anti-CTLA-4 administered as a single therapy reduced the progression of another tumor type, i.e., mouse bladder cancer induced by the MB49 cell line with low CD80 expression [6,47]. The gene discussed is CD80; the disease is urinary bladder carcinoma.